Annotation Detail
Information
- Associated Genes
- BRAF
- Associated Variants
- BRAF BRAF-CUL1
- Associated Disease
- ovarian serous carcinoma
- Source Database
- CIViC Evidence
- Description
- One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcriptome sequencing. This patient with metastatic disease after treatment with carboplatin and paclitaxel, was enrolled onto a study of paclitaxel in combination with an oral MEK inhibitor and achieved a CR. She continued to receive therapy for 7 months, until discontinuation because of the development of pneumonitis. At publication, sustained CR had lasted > 18 months.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1662
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5
- Variant URL
- https://civic.genome.wustl.edu/links/variants/656
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Ovarian Serous Carcinoma
- Evidence Direction
- Supports
- Drug
- Mitogen-Activated Protein Kinase Kinase Inhibitor
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26324360
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Mitogen-Activated Protein Kinase Kinase Inhibitor | Sensitivity | true |